Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Other Operating Expenses: 2010-2021

Historic Other Operating Expenses for Anika Therapeutics (ANIK) over the last 11 years, with Dec 2021 value amounting to $825,000.

  • Anika Therapeutics' Other Operating Expenses rose 105.27% to $825,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $6.7 million, marking a year-over-year increase of 129.34%. This contributed to the annual value of -$21.1 million for FY2021, which is 8.22% up from last year.
  • According to the latest figures from Q4 2021, Anika Therapeutics' Other Operating Expenses is $825,000, which was up 123.91% from -$3.5 million recorded in Q3 2021.
  • In the past 5 years, Anika Therapeutics' Other Operating Expenses ranged from a high of $8.7 million in Q4 2017 and a low of -$24.3 million during Q4 2018.
  • Its 3-year average for Other Operating Expenses is -$275,500, with a median of $1.8 million in 2021.
  • Per our database at Business Quant, Anika Therapeutics' Other Operating Expenses slumped by 10,200.00% in 2020 and then skyrocketed by 184.73% in 2021.
  • Anika Therapeutics' Other Operating Expenses (Quarterly) stood at $8.7 million in 2017, then slumped by 378.56% to -$24.3 million in 2018, then soared by 99.37% to -$152,000 in 2019, then slumped by 10,200.00% to -$15.7 million in 2020, then soared by 105.27% to $825,000 in 2021.
  • Its Other Operating Expenses stands at $825,000 for Q4 2021, versus -$3.5 million for Q3 2021 and $6.5 million for Q2 2021.